BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34161789)

  • 1. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis.
    Tattevin P; Dinh A; Ghout I; Mouton W; Verdier MC; Laurent F; Lemaitre F; Gatin L; Saleh-Mghir A; Crémieux AC
    Int J Antimicrob Agents; 2020 Nov; 56(5):106152. PubMed ID: 32898684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
    Tsala M; Vourli S; Georgiou PC; Pournaras S; Daikos GRL; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2019 Feb; 74(2):387-394. PubMed ID: 30376071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F; Zhou Q; Yang X; Bai Y; Cui J
    PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection.
    Gatin L; Mghir AS; Mouton W; Laurent F; Ghout I; Rioux-Leclercq N; Tattevin P; Verdier MC; Cremieux AC
    Int J Antimicrob Agents; 2019 Oct; 54(4):456-462. PubMed ID: 31319190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
    Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
    J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
    Michail G; Labrou M; Pitiriga V; Manousaka S; Sakellaridis N; Tsakris A; Pournaras S
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6028-33. PubMed ID: 24060874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.
    Gatti M; Raschi E; De Ponti F
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):65. PubMed ID: 31718688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms.
    Geladari A; Simitsopoulou M; Antachopoulos C; Roilides E
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.